Haridwar Drug Syndicate Busted: NCB Uncovers Clandestine Pharma Lab in Multi-State Operation

IMT News Desk
IMT News Desk
· 2 min read

A six-month investigation by the NCB has led to the arrest of eight individuals and the discovery of an illegal pharma lab in Haridwar involved in large-scale drug trafficking.

An investigation that began with a parcel seized at a Delhi courier facility in January 2025 has led the Narcotics Control Bureau (NCB) to uncover a large-scale drug trafficking network operating out of Haridwar. On June 6, officials dismantled a clandestine pharmaceutical manufacturing unit in Sidcul, Haridwar, exposing the illegal production of psychotropic drugs. The lab was functioning without a valid license and was supplying controlled substances for non-medical use.

The Delhi Zonal Unit of NCB used a bottom-to-top approach to trace the origin of the intercepted drugs, starting with the seizure of 3.6 kg of Codeine Phosphate tablets. Over the next few months, coordinated follow-up searches were carried out in Delhi and Ghaziabad. These efforts led to the recovery of over 9 kg of Alprazolam, 2.3 kg of Codeine Phosphate, 10,000 tablets of various controlled medicines, 1.3 kg of Pseudoephedrine, and more than 130 kg of raw materials.

The operation spanned Delhi, Uttar Pradesh, and Uttarakhand, and initial findings suggest links to international networks. A total of eight arrests have been made so far. Authorities believe the substances were being produced in bulk for illegal trade and distributed through courier networks.

This incident follows a similar crackdown by the NCB Amritsar Zonal Unit in May 2025, where a drug cartel was disrupted across Punjab and neighboring states. That operation resulted in drug seizures worth ₹547 crore and 15 arrests.

As investigations continue, NCB has called for public support to identify and report narcotics activities. Citizens can contact the National Narcotics Helpline at 1933, with assurance that all reports will remain confidential.

Through ongoing enforcement and surveillance, the NCB aims to break drug networks and uphold efforts toward a drug-free society.

Read Next

‘Heal in India’ and Beyond: Sonam Garg Sharma on Building a Seamless Global Patient Journey
Featured Article
July 14, 2026

‘Heal in India’ and Beyond: Sonam Garg Sharma on Building a Seamless Global Patient Journey

Sonam Garg Sharma, Founder & CEO of Medical Linkers, shares how her patient‑first, technology‑enabled platform is reshaping cross‑border medical journeys by tackling trust, transparency, visa and logistics barriers, and by integrating advanced tertiary care with holistic wellness to position India as a leading medical value travel destination for patients across Africa, the Middle East, Bangladesh […]
Article by: IMT News Desk
India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Why India Must Make Clinical Research a Core Part of Medical Education
Featured Article
June 30, 2026

Why India Must Make Clinical Research a Core Part of Medical Education

India stands at a pivotal moment in medical education as the National Medical Commission and the Indian Council of Medical Research move to embed clinical research, ethics, scientific writing and research methodology into training. Dr. Seema Pai, President, Indian Society for Clinical Research (ISCR), argues that clinical research should no longer be an optional academic […]
Article by: IMT News Desk
LuNGS Alliance Pushes Biomarker Testing Beyond Metros, Aims to Transform Lung Cancer Care in Smaller Indian Cities
Featured Article
June 27, 2026

LuNGS Alliance Pushes Biomarker Testing Beyond Metros, Aims to Transform Lung Cancer Care in Smaller Indian Cities

Dr. Kumar Prabhash, Professor, Medical Oncology and Head of the Solid Tumour Unit at Tata Memorial Hospital, and Director, Homi Bhabha Cancer Institute, says lung cancer patients in India’s smaller cities continue to face serious gaps in diagnosis, biomarker testing and access to targeted treatment. In this interview, he explains how the LuNGS Alliance is […]
Article by: IMT News Desk